Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CHRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CHRS

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Coherus BioSciences Inc

CHRS
Current price
0.90 USD +0.05 USD (+5.86%)
Last closed 0.85 USD
ISIN US19249H1032
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 100 537 096 USD
Yield for 12 month -48.28 %
1Y
3Y
5Y
10Y
15Y
CHRS
21.11.2021 - 28.11.2021

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California. Address: 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

4.68 USD

P/E Ratio

1.97

Dividend Yield

Financials CHRS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CHRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+266 960 000 USD

Last Year

+257 244 000 USD

Current Quarter

+7 599 000 USD

Last Quarter

+54 144 000 USD

Current Year

+149 407 000 USD

Last Year

+94 461 000 USD

Current Quarter

+4 946 000 USD

Last Quarter

+19 253 000 USD
EBITDA -77 800 000 USD
Operating Margin TTM -597.91 %
Price to Earnings 1.97
Return On Assets TTM -9.10 %
PEG Ratio
Return On Equity TTM -1 657.06 %
Wall Street Target Price 4.68 USD
Revenue TTM 272 251 008 USD
Book Value -1.58 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 229.20 %
Dividend Yield
Gross Profit TTM 153 484 000 USD
Earnings per share 0.44 USD
Diluted Eps TTM 0.44 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -75.50 %
Profit Margin -48.09 %

Stock Valuation CHRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 1.97
Forward PE 41.15
Enterprise Value Revenue 1.06
Price Sales TTM 0.37
Enterprise Value EBITDA 3.60
Price Book MRQ 73.19

Technical Indicators CHRS

For 52 Weeks

0.66 USD 2.43 USD
50 Day MA 0.83 USD
Shares Short Prior Month 31 942 421
200 Day MA 1.04 USD
Short Ratio 21.85
Shares Short 31 939 275
Short Percent 28.65 %